Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

$SUPN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $SUPN alert in real time by email
  • Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree

  • 15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2

ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3

Glazer, who has always been outspoken about his mental health struggles, wants others to know that when it comes to ADHD, there are many going through similar experiences. By gaining a clear understanding of what ADHD is, common symptoms and how it affects people's day to day lives, individuals can work with their doctors to choose the best course of action to suit their personal needs.

"I'm partnering with Supernus to help others overcome the stigmas associated with ADHD and help those diagnosed understand they are not alone," says Glazer. "I've struggled a lot in my treatment journey. Since I was diagnosed later in life as an adult, it has been difficult trying to find the right treatment. Qelbree has helped me manage my ADHD symptoms, and I have Supernus to thank for that."

October is ADHD Awareness Month, an important time to bring attention to the often complicated diagnosis and treatment journey and an opportunity for individuals to learn, educate and empower one another.

"Supernus stands with the ADHD community year-round, and especially during ADHD Awareness Month, offering solidarity, support and understanding for those living with the condition," says Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. "We're thrilled to see the impact that Qelbree has had on people living with ADHD, including Jay Glazer, and appreciate his willingness to join us during this important time of year and open up about his ADHD story of perseverance and optimism."

For more information about Qelbree, visit Qelbree.com. Patients should speak to a doctor about all the medications they take, and to see if Qelbree could be right for them.

INDICATION

Qelbree® (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION

Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child's moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You should not take Qelbree if you or your child:

Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child's doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed Warning, for Qelbree here.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

For more information, please visit www.supernus.com.

1Centers for Disease Control and Prevention. Data and Statistics About ADHD. Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/adhd/data.html.

2Castellanos, F. X. (2012). Large-Scale Brain Systems in ADHD: Beyond the Prefrontal-Striatal Model. Trends in Cognitive Science. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272832/.

3Culpepper, L., Mattingly, G. (2010). Challenges in Identifying and Managing Attention-Deficit/Hyperactivity Disorder in Adults in the Primary Care Setting: A Review of the Literature. Primary Care Companion Journal of Clinical Psychiatry.

CONTACT:

Jack A. Khattar, President and CEO

Timothy C. Dec, Senior Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

Or

MEDIA CONTACT:

Alice Sofield

Mobile: (703) 861-5654

Email: Alice.Sofield@BCW-Global.com

INVESTOR CONTACT:

Peter Vozzo

ICR Westwicke

Office: (443) 213-0505

Email: peter.vozzo@westwicke.com



Primary Logo

Get the next $SUPN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SUPN

DatePrice TargetRatingAnalyst
2/19/2025$57.00 → $36.00Overweight → Neutral
Cantor Fitzgerald
1/6/2025$57.00Overweight
Cantor Fitzgerald
9/11/2024$41.00 → $36.00Overweight → Neutral
Piper Sandler
1/3/2023$44.00 → $45.00Buy
Jefferies
12/1/2021$40.00 → $44.00Buy
Jefferies
More analyst ratings

$SUPN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Supernus to Participate in Two Upcoming Investor Conferences

    ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Barclays Global Healthcare ConferenceDate: Tuesday, March 11, 2025Fireside chat:  12:30 p.m. ETPlace: Loews Miami Beach Hotel, Miami, Fla.   Jefferies Biotech on the Beach SummitDate: Wednesday, March 12, 2025Place: Ritz-Carlton South Beach, Miami, Fla.    Investors interested in arranging a meeting with the Company'

    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

    ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, Mass. Investors interested in arranging a meeting with company management during the conference should contact the TD Cowen conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Pr

    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

    Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full year 2023.Fourth quarter 2024 net sales of GOCOVRI® increased 15% to $36.9 million, compared to the same period in 2023. Full year net sales of GOCOVRI increased 9% to $130.8 million, compared to full year 2023.Full year 2024 revenues increased 9% to $661.8 million, compared to the same period in 2023; Full year 2024 total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1) increased 25%, compared to full year of 2023.Full year 2024 operating earnings of $81.7 million, co

    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SUPN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SUPN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SUPN
SEC Filings

See more

$SUPN
Leadership Updates

Live Leadership Updates

See more
  • Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

    Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SUPN
Financials

Live finance-specific insights

See more
  • Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

    Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full year 2023.Fourth quarter 2024 net sales of GOCOVRI® increased 15% to $36.9 million, compared to the same period in 2023. Full year net sales of GOCOVRI increased 9% to $130.8 million, compared to full year 2023.Full year 2024 revenues increased 9% to $661.8 million, compared to the same period in 2023; Full year 2024 total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1) increased 25%, compared to full year of 2023.Full year 2024 operating earnings of $81.7 million, co

    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

    ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2024 financial and business results on Tuesday, February 25, 2025 at 4:30 p.m. ET. Following management's prepared remarks and disc

    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Supernus Announces Third Quarter 2024 Financial Results

    Net sales of Qelbree® increased 68% in the third quarter of 2024, compared to the same period in 2023. Net sales of Qelbree of $62.4 million and $166.9 million in the third quarter and first nine months of 2024, respectively. Net sales of GOCOVRI® increased 8% in the third quarter of 2024, compared to the same period in 2023. Net sales of GOCOVRI of $35.6 million and $93.9 million in the third quarter and first nine months of 2024, respectively. Total revenues were $175.7 million in the third quarter of 2024, an increase of 14% compared to the same period in 2023. Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales (non-GAAP)(1) increased 26% in the third quarter of 2024

    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SUPN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more